HKTDC
9.4.2024 10:55:30 CEST | Business Wire | Press release
Hong Kong Trade Development Council:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240408808037/en/
HKTDC Hong Kong Gifts & Premium Fair, Hong Kong International Printing & Packaging Fair & DeLuxe PrintPack Hong Kong will be held on 27-30 April (Photo: Business Wire)
HKTDC Hong Kong Gifts & Premium Fair
Featuring a curated selection of gift and premium products from around 4000 exhibitors from 21 countries and regions, the fair will be held at the Hong Kong Convention and Exhibition Centre from 27-30 April, with the online matching services “Click2Match” available from 20 April to 7 May. It offers an ideal platform for exhibitors to showcase their latest products, and foster networking and collaboration among industry professionals.
The Hall of Fine Designs will return as a convergence of reputed global brands, including Red A (Hong Kong), Tiny Memory (Hong Kong), YASHICA (Japan) and more. The pavilion formed by Hong Kong Exporters' Association will showcase the design skills and branding excellence of local product designers. Winning works from the Hong Kong Smart Design Awards will also be displayed to highlight the creativity and flair of Hong Kong brands to global industry players.
The anticipated Cultural & Creative Corner will captivate visitors with its vibrant showcase of designer brands and products with unique styles. Catering to the latest trends, the brand-new Outdoor & Sporting Goods zone will showcase a series of products including camping gear, dance shoes, and sporting goods.
To keep visitors abreast of the latest market information and encourage networking, there will be seminars hosted by industry players and associations to share insights on areas crucial to the sector’s development such as consumer market trends, sustainability and silver economy.
Hong Kong International Printing & Packaging Fair & DeLuxe PrintPack Hong Kong
Jointly organised by the Hong Kong Trade Development Council and CIEC Exhibition Company (HK) Limited, the two printpack Fairs will be held from 27-30 April at AsiaWorld-Expo, with the online matching services “Click2Match” available from 20 April to 7 May.
The Printing & Packaging Fair is a premier marketplace to source printing and packaging equipment, products and services. As global demand for luxury packaging grows, the acclaimed World of DeLuxe PrintPack Zone at the Fair will spin off and launch as DeLuxe PrintPack Hong Kong this year. Together, the two Fairs will host around 500 exhibitors, offering a comprehensive showcase of industry-leading solutions.
Highlighted Zones:
- Green Printing & Packaging: bio-degradable materials, upcycled products and innovative green solutions
- Food & Beverage Packaging: functional solutions designed for fresh, chilled, and processed food
- E-commerce Packaging: creative solutions for enterprises to capture e-tailing opportunities
The debut DeLuxe PrintPack will present an array of printing and packaging solutions tailored for luxury goods including jewellery, watches, cosmetics, gourmet food, and wine.
Forums and networking activities will be held share industry trends, sustainable designs and the impact of deluxe packaging on brand identity. Award-winning entries from the Hong Kong Print Awards, the Hong Kong Digital Printing Award and the GAAHK x PolyU Design - Packaging Design will be presented to showcase innovations in printpack design and production.
Register Now: https://tinyurl.com/2jrph7z2
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408808037/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom